Christopher Cabell

Christopher Cabell

Vermögen: 1 Mio $ am 31.10.2026

57 Jahre
Health Technology
Consumer Services
Commercial Services

Profil

Christopher H.
Cabell
is Chief Executive Officer at CorHepta Pharmaceuticals, Inc. since 2024.
Director at ScienceMedia, Inc. since 2020.
Independent Director at Pulmatrix, Inc. since 2020.
Member at American College of Cardiology Foundation.
President & Head-Research & Development at Inhibikase Therapeutics, Inc. starting 2025.
Formerly Chief Medical Officer & Executive Vice President at Zura Bio Ltd. from 2023 to 2024.
Chief Medical Officer & Head-Clinical Development at Emergent BioSolutions, Inc. from 2021 to 2023.
Chief Medical Officer, Head-Research & Development at Arena Pharmaceuticals, Inc. in 2020.
Senior VP & Head-Therapeutic Delivery Unit at Quintiles Transnational Corp.
from 2015 to 2017.
Chief Medical & Scientific Officer at Quintiles, Inc. (California), IQVIA RDS, Inc., and IQVIA, Inc. from 2007 to 2017.
Director at Cenduit LLC.
Director-Echocardiography Core Lab at Duke Clinical Research Institute.
Co-Chairman at US Food & Drug Administration and Cardiac Safety Research Consortium.
Associate Professor at Duke University School of Medicine.
Education includes graduate degree from Duke University, undergraduate degree from The Pennsylvania State University, and doctorate from Duke University School of Medicine.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
15.04.2026 676 564 ( 0,48 % ) 1 Mio $ 31.10.2026
28.08.2026 0 ( -.--% ) - $ 31.10.2026

Aktive Positionen von Christopher Cabell

UnternehmenPositionBeginn
INHIBIKASE THERAPEUTICS, INC. Präsident 21.02.2025
PULMATRIX, INC. Direktor/Vorstandsmitglied 23.06.2020
Direktor/Vorstandsmitglied 18.02.2020
Corporate Officer/Principal 30.04.2009

Ehemalige bekannte Positionen von Christopher Cabell

UnternehmenPositionEnde
ZURA BIO LIMITED Technik-/Wissenschafts-/F&E-Leiter 15.01.2024
EMERGENT BIOSOLUTIONS INC. Technik-/Wissenschafts-/F&E-Leiter 01.01.2023
ARENA PHARMACEUTICALS Technik-/Wissenschafts-/F&E-Leiter 01.12.2020
Technik-/Wissenschafts-/F&E-Leiter 01.09.2017
Technik-/Wissenschafts-/F&E-Leiter 22.07.2011
Sehen Sie sich die Erfahrung von Christopher Cabell im Detail an

Ausbildung von Christopher Cabell

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

68

Beziehungen ersten Grades

18

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen18

Commercial Services

Technology Services

Health Technology

Health Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Government

Health Services

Commercial Services

Technology Services

Distribution Services

Health Technology

Consumer Services

Health Technology

Cardiac Safety Research Consortium

Health Technology

  1. Börse
  2. Insider
  3. Christopher Cabell